Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer

Filipa Lynce,Matthew J. Blackburn,Rebecca Zhuo,Christopher Gallagher,Olwen M. Hahn,Maysa Abu‐Khalaf,Mahsa Mohebtash,Tianmin Wu,Paula R. Pohlmann,Asma Dilawari,Shruti R. Tiwari,Ami Chitalia,Robert Warren,Ming Tan,Ayesha N. Shajahan‐Haq,Claudine Isaacs
DOI: https://doi.org/10.1002/cncr.33620
IF: 6.9209
2021-06-22
Cancer
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, are approved to treat hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) and are associated with hematologic toxicity. African American women, who are underrepresented in CDK4/6 inhibitor clinical trials, may experience worse neutropenia because of benign ethnic neutropenia. The authors specifically investigated the hematologic safety of palbociclib in African American women with HR-positive/HER2-negative ABC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>PALINA was a single-arm, open-label, investigator-initiated study of palbociclib (125 mg daily; 21 days on and 7 days off) plus endocrine therapy (ET) in African American women who had HR-positive/HER2-negative ABC and a baseline absolute neutrophil count ≥1000/mm<sup>3</sup> (ClinicalTrials.gov identifier NCT02692755). The primary outcome was the proportion of patients who completed 12 months of therapy without experiencing febrile neutropenia or treatment discontinuation because of neutropenia. Single nucleotide polymorphism analysis was used to assess Duffy polymorphism status. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Thirty-five patients received ≥1 dose of palbociclib plus ET; 19 had a Duffy null polymorphism (cytosine/cytosine). There were no reports of febrile neutropenia or permanent study discontinuation because of neutropenia. Significantly more patients with the Duffy null versus the wild-type variant had grade 3 and 4 neutropenia (72.2% vs 23.1%; <i>P</i> = .029) and required a palbociclib dose reduction (55.6% vs 7.7%; <i>P</i> = .008). Patients with the Duffy null versus the wild-type variant had lower overall relative dose intensity (mean ± SD, 81.89% ± 15.87 and 95.67% ± 5.89, respectively; <i>P</i> = .0026) and a lower clinical benefit rate (66.7% and 84.6%, respectively). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These findings suggest that palbociclib is well tolerated in African American women with HR-positive/HER2-negative ABC. Duffy null status may affect the incidence of grade 3 neutropenia, dose intensity, and possibly clinical benefit.</p></section>
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the hematological safety issue when using palbociclib in combination with endocrine therapy among African - American women. Specifically, the study focuses on the hematological safety of palbociclib in combination with endocrine therapy for hormone receptor - positive/human epidermal growth factor receptor 2 - negative advanced breast cancer (HR - positive/HER2 - negative ABC) in African - American women with benign ethnic neutropenia (BEN). The study specifically explores the impact of the Duffy null genotype on grade 3 and 4 neutropenia caused by palbociclib, as well as the possible impact on dose intensity and clinical benefit rate. ### Research Background - **CDK4/6 Inhibitors**: CDK4/6 inhibitors, including palbociclib, are approved for the treatment of HR - positive/HER2 - negative ABC, but these drugs are associated with hematological toxicity, especially neutropenia. - **African - Americans**: African - American women are under - represented in CDK4/6 inhibitor clinical trials and may experience more severe neutropenia due to BEN. - **Duffy Antigen Receptor**: The Duffy null genotype is associated with BEN, and approximately 60% - 70% of African - Americans carry this genotype. ### Research Objectives - **Primary Objective**: To evaluate the hematological safety of palbociclib in African - American women, especially whether these patients will develop febrile neutropenia or discontinue treatment due to neutropenia during treatment. - **Secondary Objectives**: To analyze the dose delay and reduction of palbociclib, as well as the clinical benefit rate (CBR). ### Research Methods - **Design**: A single - arm, open - label, investigator - initiated phase II clinical trial. - **Inclusion Criteria**: Women who self - report as African, African - American or black, aged ≥18 years, with HR - positive/HER2 - negative ABC, and a baseline absolute neutrophil count (ANC) ≥1000/mm³. - **Treatment Regimen**: Palbociclib 125 mg once daily for 21 consecutive days, followed by 7 days of drug withdrawal, in combination with endocrine therapy (such as letrozole, anastrozole, exemestane or tamoxifen). ### Main Results - **Primary Outcome**: Among 35 patients, 31 completed at least one treatment cycle, and no febrile neutropenia or permanent discontinuation of treatment due to neutropenia was reported. - **Impact of Duffy null Genotype**: - Patients with the Duffy null genotype were more likely to develop grade 3 and 4 neutropenia than wild - type patients (72.2% vs 23.1%, P = 0.029). - Patients with the Duffy null genotype were more likely to require a reduction in the palbociclib dose (55.6% vs 7.7%, P = 0.008). - The relative dose intensity (RDI) of patients with the Duffy null genotype was significantly lower than that of wild - type patients (81.89% ± 15.87 vs 95.67% ± 5.89, P = 0.0026). - The clinical benefit rate (CBR) of patients with the Duffy null genotype was also lower (66.7% vs 84.6%). ### Conclusions - **Overall Conclusion**: Palbociclib is generally safe in African - American women, but the Duffy null genotype may affect the incidence of grade 3 neutropenia, dose intensity and clinical benefit. - **Recommendation**: Based on the research results, screening for DARC gene polymorphisms before starting palbociclib treatment is not recommended, because it is safe to start treatment at the standard dose even for patients with the Duffy null genotype. ### Limitations - **Small Sample Size**: The study has a small sample size, which may affect the generalizability of the results. - **Open - label Design**: The study is designed as an open - label study, which may introduce bias.